Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 96-109

  De Bono, Johann S ^a   Stephenson J , Joseph ^a   Baker, Sharyn D ^a   Hidalgo, Manuel ^a   Patnaik, Amita ^a   Hammond, Lisa A ^a   Weiss, Geoffrey ^a   Goetz, Andrew ^a   Siu, Lillian ^a   Simmons, Cecelia ^a   Jolivet, Jacques ^a   Rowinsky, Eric K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEAMINASE; DEOXYCYTIDINE DEAMINASE; NUCLEOSIDE ANALOG; TROXACITABINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; DYSESTHESIA; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; MALE; MELANOMA; NEUTROPENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; STEADY STATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYTOSINE; DIOXOLANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FEMALE; HALF-LIFE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; REGRESSION ANALYSIS; SALVAGE THERAPY; STATISTICS, NONPARAMETRIC; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036139779     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.96     Document Type: Article

References (26)

1. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration
2. Deoxycytidine deaminaseresistant stereoisomer is the active form of (+/-)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication
3. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication in vitro
4. Activity of (-)-2′-deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units
5. Troxacitabine (BCH-4556)
6. Mechanisms of uptake and resistance to Troxatyl, a novel deoxycytidine nucleoside analog, in solid-tumor and leukemic cell lines
7. Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells
8. Dose scheduling effects on the anti-tumor activity of BCH-4556 against human tumor xenografts in nude mice
9. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolanecytidine), in human renal cell carcinoma xenograft tumor models
10. The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts
11. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo
12. Prediction of creatinine clearance from serum creatinine
13. Enantioselectivity in drug action and metabolism: Influence on dynamics
14. Ara-C: Cellular and molecular pharmacology
15. High molecular weight DNA fragmentation: A critical event in nucleoside analogue-induced apoptosis in leukemia cells
16. Preclinical, pharmacologic, and phase I studies of gemcitabine
17. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial
18. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
19. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia
20. A phase I study of the L-nucleoside beta-L-dioxolane-cytidine (BCH-4556) given as a 30minute infusion every 21 days
21. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia
22. Gemcitabine: Preclinical pharmacology and mechanisms of action
23. Pharmacokinetics and dosage reduction of cis-diamine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function
24. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
25. Prediction of carboplatin clearance from standard morphological and biological patient characteristics